Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04877093 · ClinicalTrials.gov registry record · Phase 3

Repurposing Low-Dose Clonidine for PTSD in Veterans

A Phase 3 study of PTSD and Sleep, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
Phase 3
Development phase
32
Enrollment target
1
Study location

NCT04877093 is a Phase 3 study of PTSD and Sleep that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 32 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04877093, a Phase 3 study of PTSD and Sleep, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
Phase 3
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.

Interventions

  • OTHER Placebo
  • DRUG Clonidine Pill

Study Locations (1)

Wisconsin

  • Aurora Psychiatric Hospital - Wauwatosa

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2023-06-01
Est. Completion 2026-03-31
Phase Phase 3

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT04877093

The ClinicalTrials.gov registry entry for NCT04877093 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (89% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04877093 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT04877093 about?

NCT04877093 is a clinical study titled "Repurposing Low-Dose Clonidine for PTSD in Veterans". Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.

What is the current status of trial NCT04877093?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2023-06-01. Estimated completion is 2026-03-31.

What conditions does trial NCT04877093 study?

This clinical trial studies the following conditions: PTSD, Sleep, Posttraumatic Stress Disorder.

What interventions are being tested in trial NCT04877093?

The interventions under investigation include: Placebo (OTHER), Clonidine Pill (DRUG).

Who is sponsoring clinical trial NCT04877093?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04877093 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.